ALA hydrochloride

SKU: orb1224731

Description

5-Aminolevulinic acid hydrochloride is an intermediate in heme biosynthesis in the body and the universal precursor of tetrapyrroles.(In Vitro):5-Aminolevulinic acid hydrochloride (ALA) is a non-fluorescent prodrug that leads to intracellular accumulation of fluorescent porphyrins in malignant gliomas-a finding that is under investigation for intraoperative identification and resection of these tumours. Median follow-up was 35.4 months (95% CI 1.0-56.7). Contrast-enhancing tumour was resected completely in 90 (65%) of 139 patients assigned 5-aminolevulinic acid compared with 47 (36%) of 131 assigned white light (difference between groups 29% [95% CI 17-40], p<0.0001). Patients allocated 5-aminolevulinic acid had higher 6-month progression free survival than did those allocated white light (41.0% [32.8-49.2] vs 21.1% [14.0-28.2]; difference between groups 19.9% [9.1-30.7], p=0.0003, Z test) . 5-ALA alone proved to be insufficient in attaining gross total resection without the danger of incurring postoperative neurological deterioration. Furthermore, in the case of functional grade III gliomas, iMRI in combination with functional neuronavigation was significantly superior to the 5-ALA resection technique.

Key Properties

• CAS Number: 5451-09-2
• MW: 167.59
• Purity: >98% (HPLC)
• Formula: C₅H₁₀ClNO₃
• SMILES: Cl.NCC(=O)CCC(O)=O
• Target: Amino Acids and Derivatives
• Solubility: Ethanol: 6 mg/mL (35.8 mM); Water: 34 mg/mL (202.87 mM); DMSO: 34 mg/mL (202.87 mM)

Bioactivity

• In Vitro:
  5-Aminolevulinic acid hydrochloride (ALA) is a non-fluorescent prodrug that leads to intracellular accumulation of fluorescent porphyrins in malignant gliomas-a finding that is under investigation for intraoperative identification and resection of these tumours. Median follow-up was 35.4 months (95% CI 1.0-56.7). Contrast-enhancing tumour was resected completely in 90 (65%) of 139 patients assigned 5-aminolevulinic acid compared with 47 (36%) of 131 assigned white light (difference between groups 29% [95% CI 17-40], p<0.0001). Patients allocated 5-aminolevulinic acid had higher 6-month progression free survival than did those allocated white light (41.0% [32.8-49.2] vs 21.1% [14.0-28.2]; difference between groups 19.9% [9.1-30.7], p=0.0003, Z test). 5-ALA alone proved to be insufficient in attaining gross total resection without the danger of incurring postoperative neurological deterioration. Furthermore, in the case of functional grade III gliomas, iMRI in combination with functional neuronavigation was significantly superior to the 5-ALA resection technique.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

5-ALA | δ-Aminolevulinic Acid

Quick Database Links

Gene Symbol

Amino Acids and Derivatives